Introduction
Interferons (IFNs) are the first line of defense against viral infections in mammals. In addition to their antiviral activity, they have also shown several antiproliferative and immunomodulatory effects [1] . Human type I IFNs includes a multigene family of different IFN-α subtypes (13 subtypes) and a single IFN-β. The IFN-α subtypes are very similar at the structural level and all of them interact with the same receptor, but differences have been found in their biological activity [2] .
Hepatitis C virus (HCV) infection is notably by the tendency to develop chronicity, being the main cause of hepatic disease. 130 million people are chronically infected by the virus, which resembles that the virus has developed mechanisms particularly efficient to avoid the antiviral system. Six main genotypes (1-6) distinguish the global geographic diversity of HCV and a multitude of closely related subtypes (a-j) within these genotypes are also defined and may influence clinical outcome and treatment options [3] . Current treatment consists in the combined administration of pegylated IFN-α2 and Rivabirin. Although main of the patients infected with genotype 2 or 3 show a sustained virological response (SVR) to the current standard of care, only 50% of those infected with genotype 1 achieve SVR with this therapeutic strategy. As more than 80% HCV infected patients in Western world and Asia correspond to genotype 1, an increase in the efficacy of IFN-α treatment is urgently needed.
IFN-α5 has been found to be the main IFN-α subtype expressed in liver of healthy people and is markedly decreased in the livers of patients with chronic HCV infection as compared with patients with other liver diseases (including hepatitis B virus chronic infection) [4] . It has also been demonstrated that it induces stronger signaling and higher expression of antiviral genes than IFN-α2 [5] . This data suggests that exogenous administration of IFN-α5 to HCV chronically infected patients might be very useful for the effective virus clearance over the current use of IFN-α2. These findings warrant preclinical studies in order to evaluate its safety and efficacy in animal models, and its subsequent clinical development.
In order to conduct successful preclinical and clinical studies for regulatory purposes, IFN-α5 has to be quantified in biological fluids in order to obtain pharmacokinetic and toxicokinetic data to support and interpret the pharmacological and toxicological findings. Moreover, the quality of these pharmacokinetic and toxicokinetic studies is directly related to the quality of the underlying bioanalytical data; so, the validation of the bioanalytical method is a critical requirement [6] .
IFN-α5 is a very active substance, so the dose administered to animals or humans is very low, leading to very low concentration levels in biological samples. The aforementioned, together with the fact that low volumes of biological samples could be extracted at each time in pharmacokinetic studies so as to avoid altering the individual volemia, explains the need to use very sensitive analytical methods in the determination of IFN-α5. Attempts of our research group to quantify it using chromatographic methods (HPLC, LC-MS, etc.) have not given good results regarding sensitivity. In addition, there are no ligand-binding assays capable of specifically detecting because there are no IFN-α5-specific antibodies. Therefore, the idea of quantifying IFN-α5 through its antiviral activity by means of an antiviral assay (AVA) arose.
Historically, antiviral assays have been the first type of biological assays developed for the quantification of IFN activity, but no validation data has been reported for any of them. Some combinations of suitable cell lines with viruses have demonstrated to be highly sensitive, although they showed considerable inter-assay variations, mostly because of the staining and fixing procedures needed to end the AVA.
Due to the aforementioned, the aim of this study was to develop a very reproducible, sensitive and rapid method in order to provide robust dose-response data for IFN-α5 activity. For this purpose, an AVA, with the combination of the HeLa cell line and the encephalomyocarditis virus (EMCV), has been integrated for the first time with the Vialight ® Plus assay. This method has been validated, under GLP conditions, in order to quantify IFN-α5 activity in macaque (Macaca fascicularis) and human serum. Human serum has been chosen due to the fact that it will be the main matrix in clinical studies. The macaque was chosen because it is the most adequate animal model for the preclinical evaluation of IFN-α5, given the fact that it is an interferon of human origin and that its pharmacological activity and interaction with the receptor is known to be speciesspecific [7] .
Therefore, the novelty of this study consists on the integration for the first time of an AVA with EMCV in HeLa cells, with Vialight ® Plus assay for processing of AVA, and on its validation under GLP conditions to a level which ensures precise and accurate measurements of IFN-α5 activity in serum samples. All the expected criteria for these most widely available biological assays for IFNs have been achieved. 
Materials and methods

Reagents
Cell culture
HeLa cells (CCL-2), which are human epithelial cervix adenocarcinoma cells, were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).
Cells were incubated in DMEM supplemented with 10% fetal bovine serum and 1%
antibiotic (Penicillin-Streptomycin) (complete DMEM medium).
Test item (IFN-α5) and serum samples
IFN-α5 was provided by Sicor Biotech UAB (Vilnius, Lithuania). IFN-α5 was produced through recombinant DNA technology in E. Coli and a structural characterization and evaluation of physicochemical properties of purified IFN-α5 protein were carried out [8] . The original test item was used to obtain a stock solution (SS) of IFN-α5 at 1 x 10 8 IU/mL in culture medium (complete DMEM medium). This SS was aliquoted and stored at -80 ºC until its use in the preparation of the standard curves and for the spiking of the serum samples.
The serum was obtained from six Macaca fascicularis macaques at the animal care facility of the University of Navarra and also from ten healthy volunteers at the Clínica Universidad de Navarra (CUN) blood extraction service. Blood was collected in BD Vacutainer ® SST extraction tubes with serum separator gel, maintained 1 hour at ambient temperature in a vertical position and centrifugated following the manufacturer's instructions. The obtained serum was aliquoted and stored at -80 ºC.
Extraction of blood from the animals and volunteers was approved by the Animal Experimentation Ethics Committee and Research Ethics Committee of the University of Navarra, respectively.
The serum used for the spiking process, with the exception of that used in the study of the selectivity parameter, was a pool of blank macaque or human serum.
Antiviral assay procedure
The bioassay was conducted on a 96-well cell culture plate compatible with luminometry (opaque white plate with clear bottom) (figure 1). The inner 60 wells were only used due to the uneven response of the outer wells. The standards (standard curve), the controls (growth control and viral effect control) and the samples (blank and spiked, or the real samples of a study) were included in the plate, each in triplicate (figure 2).
The growth control (nonvirus-treated HeLa cells) was used for evaluating the normal growth of the cells, and the viral effect control (HeLa cells treated with virus) was necessary in order to evaluate the viral cytopathic effect in the absence of IFN-α5.
First, 50 µL of complete DMEM medium was added to the control wells (growth control and viral effect control wells). 50 µL of each point of the standard curve and 50 µL of each sample (blank and spiked, or the real samples of a study) were then added to the corresponding wells.
Next, 20,000 HeLa cells per well were seeded, adding 100 µL of 2 x 10 5 cell/mL cell suspension to all the wells of the plate. The plate was incubated in an incubator at 37ºC and with 5% CO 2 for at least 12 hours.
After that, an EMCV virus dilution was prepared in order to produce a complete cytopathic effect (in the viral effect control) starting with the stock concentration of the EMCV virus in complete DMEM medium (about 2 x 10 7 pfu/mL). The dilution was agitated with a vortex and 50 µL were added to all the wells except to the growth control wells. Then, the plate was incubated in an incubator at 37ºC and with 5% CO 2 for 16 hours.
Before proceeding to the plate washing and development process, the cells are observed in order to ensure that the cytopathic effect of the virus is complete. This is accomplished by observing the viral effect control wells under a microscope (x4, Eclipse TS100, Nikon), in which cell lysis should have occurred as a result of the viral effect, and by comparing the wells with the growth control wells in which the cells ought to be at confluence. Next, the luminescence reading was carried out using the 
Assay optimization
In order to develop an adequate AVA, different aspects were optimized. The manufacturer´s protocol for the Vialight ® Plus kit allows for the two reagents (Cell Lysis Reagent and ATP Monitoring Reagent) to be added directly to the culture well without the requirement of cell washing or medium removal. In order to evaluate the lack of sensitivity loss in our assay conditions, the influence of the culture medium and matrix (serum) on the reagents from the kit was studied. Therefore, cell viability was measured following the kit protocol on cells grown in culture medium or at different proportions of serum in culture medium. An evaluation was also carried out in order to determine the influence of the matrix on the accuracy and precision parameters of the standard curves, and the adequate quantification interval. Therefore, comparisons were made between standard curves obtained with IFN-α5 in culture medium and IFN-α5 in different proportions of serum in culture medium.
Assay validation
Selectivity
The capability of the bioassay to quantify IFN-α5 in the presence of other matrix (macaque Macaca fascicularis and human serum) components was evaluated. In order to do so, a study was carried out with serum obtained from five animals and ten volunteers. For each animal or volunteer, blank serum samples (basal) and serum samples spiked with two different IFN-α5 activities were compared. Each sample was analyzed in triplicate.
The bioassay was considered to be selective if the responses of the basal serum samples
were not higher than those obtained with the viral effect control taking an error of 30% into account. In addition, an increase in the signal of spiked serum samples for each individual should be observed when compared to the blank serum samples. The coefficients of variation (CV) and relative errors (RE) for each spike serum sample and individual must not be higher than the CV expected for the bioassay (30%).
Standard curves
Standard curves were prepared in different proportions of serum in the culture medium ranging from 0.7 to 25 IU/mL of IFN-α5. In order to obtain a large quantification range, different dilutions of serum with culture medium were prepared: 1/10, 1/100, 1/300, Precision and accuracy of the standard curves were studied.
The acceptance criteria for the standard curves was to have a minimum of six points, an R 2 ≥ 0.98, with a CV and a RE of the three replicates and on six different days (3 x 6 = 18 replicates), ≤ 30%.
Precision and accuracy
The precision expresses the capability of an assay to provide closeness of agreement between results. Accuracy shows the capability of an assay to provide results that are as close as possible to the theoretical value. In order to assess these two parameters on the spiked serum samples, they were analyzed in the AVA on six different days. The activity corresponding to the spiked serum samples analyzed and the dilution used are described in table 1. The spiked samples are 100% serum. The acceptance criteria were that the CV and the RE of the three replicates, on six different days, must be ≤ 30% in at least 75% of the spiked samples. In addition, the sum of the % of the CVs plus the % of the RE for the six repetitions made (3 x 6 = 18 replicates) must be ≤ 40%.
Robustness
The test item batch and the development kit reagent batch may vary in subsequent studies using this quantification method. In order to evaluate the robustness of the AVA in these terms, a study was made with two batches of IFN-α5 and two batches of the reagents from the Vialight ® Plus kit.
Standard curves were obtained with each batch of IFN-α5. In addition, the same IFN-α5 was used to obtain standard curves but processed with two batches of the reagents from the Vialight ® Plus kit. For each IFN-α5 or kit batch change, each standard curve must comply with the repeatability and accuracy criteria established (CV ≤ 30%; RE ≤ 30%) when extrapolated within the other standard curve.
Sample stability
The stability of IFN-α5 in macaque and human serum in storage at -80 ºC was determined. The stability of IFN-α5 in human serum (10 and 2000 IU/mL) after 1 and 3 consecutive freeze-thaw cycles, and after 2 hours at RT and on ice before its quantification, was also studied. As in the rest of the parameters studied, each sample was analyzed in triplicate.
IFN-α5 was considered to be stable following 1 or 3 consecutive freeze-thaw cycles or after 2 hours at RT and on ice before its quantification if the mean of the activity levels measured for each condition was within the interval formed by the nominal value (activity value at which the sample was spiked: 10 or 2000 IU/mL), taking into account the assay error (RE ≤ 30%).
Finally, the stability of the SS of IFN-α5 in culture medium (1 x 10 8 IU/mL) was also evaluated after approximately 1 month in storage at -80 ºC, comparing it with a SS prepared on the day of use. Standard curves were obtained with both SS on the same plate, and the mean luminescence values obtained with the IFN-α5 SS frozen for 1 month were plotted against the mean luminescence values obtained with the SS prepared at that moment. The IFN-α5 SS frozen at -80 ºC was considered to be stable if a line was obtained with a value of R 2 ≥ 0.99 whose ordinate at the point of intersection includes 0, with a probability of 95%, and whose slope includes 1 with a probability of 95%.
Quantification limit
The lowest level of IFN-α5 that reached a good quantification, with adequate precision and accuracy values, was defined as the limit of quantification and it was included as the lowest level in the standard curve.
Results
Optimization
It was observed that the culture medium and the matrix (serum) interfere with the lysis reagent of the Vialight ® Plus kit. A much lower response was observed in those wells in which the lysis reagent was added directly to the culture medium, the serum, or a mixture of both. Therefore, it was decided to introduce a washing step at the plate development stage in the manufacturer's protocol.
The serum interfered in the AVA, promoting cell growth which, in turn, gave rise to a different response between the IFN-α5 and the virus. It was observed that the greater the proportion of serum in the well, the greater the response, meaning the greater the cell growth. Inter-plate cell growth variability was also observed. Due to these observations, both the samples (blank, spiked or the real samples of a study) and the standard curve need to be tested in the same proportion of serum and culture medium, and also on the same plate. The results of this study suggest also that the lowest proportion of serum in complete DMEM medium at which the AVA must be validated is 1/10. It was confirmed that lower dilutions of serum in complete DMEM medium, for example 1/2 or 1/5, did not meet the validation established criteria.
Finally, after evaluating different concentrations in order to determine the quantification interval (from 0.32 to 83.32 IU/mL), a range of 0.7 to 25 IU/mL of IFN-α5 was considered to be adequate because quantification of the analyte with good values of precision and accuracy was achieved.
Selectivity
The bioassay was confirmed to be selective, by demonstrating that the AVA was capable of quantifying IFN-α5 in the presence of other components in the serum of five different macaques and ten volunteers. The responses of the basal serum samples were not higher than those obtained with the viral effect control taking the method error into account (table 2) . In addition, the signal was observed to increase when comparing the blank serum samples with the spiked serum samples for each individual. After calculating the CV and RE for the results obtained for each spiked sample and all the individuals, this was ≤ 30% (tables 3-4). The noninfluence of each individual on the reproducibility of the results was therefore also demonstrated.
Standard curves
Standard curves were obtained with a quantification interval from 0.7 to 25 IU/mL for the different proportions of serum in culture medium (1/10, 1/100, 1/300, 1/5000 and 1/10000 for macaque serum; 1/10 and 1/100 for human serum), with a minimum of six points and with a value for R 2 ≥ 0.98 ( figure 3) ; for the triplicate analysis, both CV and RE were ≤ 30% on six different days. Taking into account the dilution factor to be applied in the problem serum samples (1/10, 1/100, 1/300, 1/5000 and 1/10000), this quantification interval will allow samples to be quantified within an interval from 7 to 250000 IU/mL in macaque serum, and from 7 to 2500 IU/mL in human serum.
Precision and accuracy
In the repeatability and intermediate precision study with serum samples spiked with IFN-α5, precise measurements were obtained, where 75% of the points gave a value of CV ≤ 30% (table 5 ). In the within-and between-day accuracy studies, the measurements gave an RE ≤ 30% (table 6 ). In addition, the sum of the % of the CV plus the % of the RE in the six repetitions carried out was ≤ 40% (table 7) .
Robustness
The robustness of the bioassay was demonstrated by changing the IFN-α5 batch and the batch of reagents of the development kit (Vialight ® Plus). The measurements complied with the established criteria of repeatability and accuracy (tables 8-9).
Sample stability
In all the conditions evaluated, IFN-α5 remained stable. IFN-α5 in macaque serum was stable at -80 ºC for a two week time interval, and up to 6 months in human serum, as the confidence interval of the slopes with a p=0.05 included 0 (tables 10-13). Moreover, IFN-α5 was also stable in human serum after 1 and 3 consecutive freeze-thaw cycles and after 2 hours at RT and on ice before its quantification.
IFN-α5 SS was stable for 39 days frozen at -80 ºC given the fact that a line was obtained (y=0.9604x -534.98) with R 2 ≥ 0.99 whose ordinate at the point of intersection included 0 (-1518.2413, 448.2736) with a probability of 95% and whose slope included 1 (0.8998, 1.0209) with a probability of 95%.
Discussion
The regulatory agencies demand that the validation of the bioanalytical methods be developed according to the guidelines currently in force [9] [10] [11] . However, no specific guidelines regarding these particular bioassays exist. Furthermore, the available guidelines, where the acceptance criteria of the essential parameters to be studied are This bioassay is not a ligand specific assay, but it allows the quantification of IFN-α5 present in the samples through its activity. Antiviral efficacy was determined by measuring the ATP level in cells that were protected from the viral cytopathic effect by the presence of IFN-α5. This is a very important aspect that the methods that are specific have to resolve, thereby needing a correlation between the product concentration measured and the biological response evaluated on a bioassay [14] . Although, it is not specific for IFN-α5, the AVA was confirmed as being selective because it demonstrated that it was capable of quantifying IFN-α5 activity in the presence of other components in the serum. The responses of the macaque and volunteers´ basal serum samples were not higher than those obtained with the viral effect control. These samples did not show any antiviral activity in our assay conditions. Only when the samples were spiked with IFN-α5, antiviral activity was measured, and furthermore, with good precision and accuracy.
The analysis of basal serum samples from five animals and ten volunteers, also demonstrated the noninfluence of each individual on the reproducibility of the results.
Standard curves were obtained with a quantification interval from 0.7 to 25 IU/mL for the different selected proportions of serum in culture medium, allowing samples to be quantified within an interval from 7 to 250000 IU/mL in macaque serum, and from 7 to 2500 IU/mL in human serum. This interval permits quantification from very low levels, necessary for human IFN-α5 pharmacokinetic profile, to very high levels that could be achieved in repeated dose toxicokinetic studies in animals. Taking into account the data of the antiviral activity per mg of protein and protein content of the IFN-α5 provided by the manufacturer, the bioassay was capable of measuring the activity of IFN-α5 in the range of pg/mL. This limit of detection is quite low and difficult to obtain with other analytical methods.
Assay precision and accuracy has been set at 30% for both inter-and intra-assay variations (within and between days). This error percentage is higher than those permitted in the guidelines [9, 11] . For the ligand-binding assays, the acceptance criteria for calibration standards (standard curve) and spiked samples is that a minimum of 75% and 67% of the samples, respectively, should have an error no greater than 20%, or 25%
for the low and high points [15] . In this type of biological activity assays, it is usual to have larger variations, more than with chromatographic or ligand-binding assays, due to inherent biological sources of variation that are not completely controllable (cell growth, virus activity, larger assay times, etc.). Our validation data has shown that if these variations are known, assumed and reflected in the assay performance acceptance criteria, the assay can be appropriate for its intended use. Recent publications regarding bioanalytical method validation for macromolecules and biomarkers are also supporting the idea that the levels of precision and accuracy do not necessarily have to be linked to any particular threshold, but should be scientifically justified so that the variability and accuracy of the assay are acceptable for its purpose [14] .
Another advantage is that the same bioassay with the same procedure has shown to be valid for both macaque and human serum. Furthermore, the bioassay has demonstrated the stability of the IFN-α5 in macaque and human serum stored at -80 ºC, thereby allowing sample conservation without loss of its properties for several days or months.
It was assumed that a 15-day interval was enough for measuring all the samples of the preclinical studies. However, for human samples, stability for up to 6 months was studied because the patient recruitment for clinical trials is not always easy and can often involve long time periods. This stability allows measuring human serum samples extracted during a 6 months period at the same time. Furthermore, the bioassay showed the stability of IFN-α5 in human serum after 1 and 3 consecutive freeze-thaw cycles, a great advantage for repeating the measurements of these valuable human samples.
In the regulatory field, these results can also contribute to the improvement of the specific requirements and recommendations established for different assays and validation procedures by the regulatory bodies. This work also supports the idea of fitting the validation procedures and requirements for the different assays and purposes.
In conclusion, this study presents novel integration of an AVA with EMCV in HeLa cells with Vialight ® Plus assay. In view of the results obtained, this AVA is valid for quantifying IFN-α5 activity in macaque Macaca fascicularis and human serum in order to generate reliable pharmacokinetic and toxicokinetic data. The bioassay has been successfully applied to the study of the pharmacokinetic profile of IFN-α5 after subcutaneous and intravenous administration to macaques and to a 31-day repeated dose toxicokinetic study after subcutaneous administration of IFN-α5 to macaques.
Following the positive assessment of the regulatory bodies, the bioassay is also currently being applied to a clinical trial in treatment-experienced patients with genotype-1 chronic hepatitis C.
Executive summary
• Assay: A novel integration of an antiviral assay (AVA) against the cytopathic effect of the encephalomyocarditis virus in HeLa cells with a very sensitive method for AVA processing, Vialight ® Plus assay, is presented for IFN-α5 activity quantification.
• This bioassay is not a ligand specific assay, but it allows the quantification of IFN-α5 present in the samples through its activity.
• Assay validation: The validated bioassay meets suitable acceptance criteria for these types of biological assays.
• Selectivity: The AVA was confirmed as being selective because it demonstrated that it was capable of quantifying IFN-α5 activity in the presence of other components in the serum.
• Standard curves: Standard curves were obtained with a quantification interval from 0.7 to 25 IU/mL for the different selected proportions of serum in culture medium, allowing samples to be quantified within an interval from 7 to 250000 IU/mL in macaque serum, and from 7 to 2500 IU/mL in human serum.
• Sensitivity: The bioassay was capable of measuring the activity of IFN-α5 in the range of pg/mL showing a high sensitivity.
• Precision and accuracy: Assay precision and accuracy has been set at 30% for both inter-and intra-assay variations (within and between days).
• Minimum required dilution: the minimum required dilution for samples at which the AVA must be performed is 1/10 (serum in complete DMEM medium). Samples that need additional dilution should be diluted with complete DMEM medium and in all cases, the standard curve need to be tested in the same proportion of serum and culture medium of the samples.
• Regulatory acceptance: In the regulatory field, these results can contribute to the improvement of the specific requirements and recommendations established for different assays and validation procedures by the regulatory bodies.
Future perspective
Focus our research on bioanalytical assay development for therapeutic proteins. --Point ruled out for non-compliance with the established criterion. 
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